Creative Medical Technology Holdings, Inc. (CELZ): R&D Expense
$2.26M
Year ended 2025-12-31
$2.02M
Trailing 12 months to 2026-06-30
-28.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.26M | -5.9% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $2.40M | +21.8% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $1.97M | -68.6% | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | $6.27M | n/m | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $109.2K | n/a | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | $0 | -100.0% | 2021-03-17, From 2019-01-01 |
| 2018-12-31 | $96.6K | -62.9% | 2020-04-06, From 2018-01-01 |
| 2017-12-31 | $260.1K | +204.8% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $85.3K | n/a | 2018-03-29, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.26M | -5.9% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $37.59M | +9.4% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $20.66M | -37.7% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
Compare CELZ, SNTI, ENTX, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗